Table 1 Patients characteristics
Low dose (5 × 107), n = 6 | High dose (7 × 108), n = 21 | |
|---|---|---|
Age (years) | 56 ± 10 | 60 ± 9 |
Male sex (%) | 100 | 95 |
Body mass index | 28 ± 5 | 28 ± 3 |
Hypertension [n(%)] | 2 (33) | 5 (24) |
Diabetes [n(%)] | 0 | 1 (5) |
TnI max (μg/L) | 52 ± 47 | 51 ± 56 |
Infarct-related vessel [n(%)] | ||
LAD | 3 (50) | 6 (29) |
CX | 0 | 0 |
RCA | 3 (50) | 14 (67) |
LOM I | 0 | 1 (5) |
LVEF at baseline (%) | 47.4 ± 9.2 | 44.4 ± 6.3 |
LVEF at 4 months' follow-up (%) | 50.5 ± 13.2 | 52.3 ± 11.6 |
TIMI flow before PCI [n(%)] | ||
0 | 2 (33) | 4 (19) |
1 | 1 (17) | 2 (10) |
2 | 1 (17) | 3 (14) |
3 | 1 (17) | 9 (43) |
TIMI flow after PCI [n(%)] | ||
1 | 0 | 0 |
2 | 1 (17) | 2 (10) |
3 | 4 (33) | 17 (81) |
%Stenosis of the infarct-related artery before PCI | 95 ± 5 | 93 ± 7 |
Time from STEMI to BMC injection (h) | 268 ± 162 | 214 ± 94 |
Number of injected BMCs | ||
Number of mononuclear cells (× 106) | 54 ± 22 | 701 ± 254 |
Number of CD34+ cells (× 106) | 0.75 ± 0.46 | 8.9 ± 5.1 |
Adenosine infusion [n(%)] | 0 | 9 (43) |
Medication at discharge [n(%)] | ||
ASA | 6 (100) | 20 (95) |
Clopidogrel | 6 (100) | 21 (100) |
Beta-blocker | 6 (100) | 21 (100) |
ACE inhibitor/AT II receptor blocker | 6 (100) | 21 (100) |
Statin | 6 (100) | 18 (86) |
Diuretic | 2 (33) | 9 (43) |